Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/01/2855452/0/en/Biomea-Fusion-Inc-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/04/01/2855226/0/en/Biomea-Fusion-Highlights-Initial-Data-from-the-First-Two-Type-1-Diabetes-Patients-Dosed-with-BMF-219.html
https://www.globenewswire.com/news-release/2024/04/01/2855216/0/en/Biomea-Fusion-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Corporate-Highlights.html
https://www.globenewswire.com//news-release/2024/03/06/2841090/0/en/Biomea-Fusion-Presents-Patient-Cohorts-in-COVALENT-111-Displaying-a-Durable-Placebo-Adjusted-Mean-Reduction-of-up-to-1-4-in-HbA1c-While-Off-Therapy-at-Week-26-after-BMF-219-s-28-Da.html
https://www.globenewswire.com//news-release/2024/03/01/2839070/0/en/Biomea-Fusion-Inc-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com//news-release/2024/01/09/2806502/0/en/Biomea-Fusion-Highlights-Recent-Updates-and-Anticipated-2024-Corporate-Milestones-at-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2024/01/08/2805534/0/en/Biomea-Fusion-Announces-Dosing-of-First-Type-1-Diabetes-Patient-in-Phase-II-Study-COVALENT-112-with-BMF-219.html
https://www.globenewswire.com//news-release/2024/01/02/2802929/0/en/Biomea-Fusion-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/12/11/2793942/0/en/Biomea-Fusion-Presents-Achievement-of-Minimal-Residual-Disease-Negativity-MRD-neg-in-First-Complete-Responder-from-Ongoing-Phase-I-Study-COVALENT-101-of-BMF-219-in-Patients-with-Re.html
https://www.globenewswire.com//news-release/2023/12/09/2793448/0/en/Biomea-Fusion-Announces-Near-Doubling-the-Percentage-of-Patients-with-Durable-HbA1c-Reduction-in-the-200-mg-Dose-Cohorts.html